New Electromedical Technologies
Strategic Partner to Aid in Driving
Awareness and Sales
-
High profile firm WireBuzz boasts relationships with Fortune
500 firms and nation's top health care companies
-
Industry leading digital marketing agency
renowned for driving awareness and online business
-
WireBuzz poised to aid Electromedical Technologies in
onboarding new distributors and customers
SCOTTSDALE,
AZ --
December 7, 2020 -- InvestorsHub NewsWire
-- Electromedical Technologies,
Inc. (OTCQB:
EMED )
(the "Company"), a pioneer in the development and manufacturing of
bioelectronic devices, including the FDA cleared
WellnessPro+, is pleased to announce
its new strategic partnership with
WireBuzz, LLC, (www.wirebuzz.com) an award-winning video and web
design agency. The Company elected to work
with WireBuzz based upon its renowned reputation for
content production, advanced marketing, and specifically,
its impressive
online customer conversion capabilities.
In its first stage,
WireBuzz
is revamping the Company website to emulate the style and success
of sites for WireBuzz Fortune 500
clients, and
others. Future steps include
the production of
new marketing tools including video content for use by
Electromedical Technologies' distributors and influencers. WireBuzz
produces more than 3,000 videos each year, which are extremely
powerful and effective visual sales resources. The use of online
content marketing is one of the most successful sales methods in
the current COVID-19 environment and is expected to be a major
driver of product sales, going forward.
In addition to its video
marketing capabilities, WireBuzz also provides strategy and messaging
development, sales process optimization and automation, and diverse
content marketing campaigns.
Matthew Wolfson, Founder and
CEO of EMED, commented, "We are thrilled to be working
with the WireBuzz team. Their reputation as effective customer
conversion specialists through video production and marketing made
it a no-brainer. Plus, we believe that the upgrading of our website
in a style that emulates the top health care device companies sets
the stage for Electromedical Technologies to reach that upper tier,
going forward. The new site will go live later this month. In
addition, we look forward to sharing new videos and testimonials
with our customers, shareholders, and prospective new customers
seeking an effective, non-invasive product to treat chronic pain.
With over $4 million in inventory available for sale, upcoming
campaigns could drive product sales as we head into
2021."
About
Electromedical Technologies
Headquartered in Scottsdale
Arizona, Electromedical Technologies, Inc. is a commercial stage,
FDA cleared, bioelectronic medical device manufacturing company
initially focused on the treatment of various chronic, acute,
intractable, and post-operative pain
conditions. Through university collaboration agreements the company
is working to develop a comprehensive research program in defining
the effects of electro-modulation on the human body by studying the impacts
of electrical fields in cell signaling and effects on virus
assembly and immune responses with the goal of improving human
wellbeing. The company's current cleared product indications are
for chronic acute post traumatic and post-operative, intractable
pain relief.
Our animal studies do not
involve any human testing, and are not related to our current
products. We are conducting this research to augment and advance
the science of electro-modulation in healthcare. The United
States Food and Drug Administration has not reviewed or approved
our animal research studies
For more information,
visit www.electromedtech.com.
Safe Harbor
Statement
This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations reflected in the
forward-looking statements and the assumptions upon which they are
based are reasonable, we can give no assurance or guarantee that
such expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous factors and uncertainties, including but
not limited to: adverse economic conditions, competition, adverse
federal, state and local government regulation, international
governmental regulation, inadequate capital, inability to carry out
research, development and commercialization plans, loss or
retirement of key executives and other specific risks. To the
extent that statements in this press release are not strictly
historical, including statements as to revenue projections,
business strategy, outlook, objectives, future milestones, plans,
intentions, goals, future financial conditions, events conditioned
on stockholder or other approval, or otherwise as to future events,
such statements are forward-looking, and are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. The forward-looking statements contained in this
release are subject to certain risks and uncertainties that could
cause actual results to differ materially from the statements
made.
Corporate
Contact:
Electromedical Technologies,
Inc.
Matthew
Wolfson
Tel:
1.888.880.7888
email:
ceo@electromedtech.com
https://electromedtech.com